Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$19.73 – $20.68
83% from low
Borrow rate
9.57%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| IPDPDividend Performers ETF | $20.52 | +0.22% | $22M | — |
| BLLDJPMorgan Sustainable Infrastructure ETF | $48.77 | +0.02% | $20M | — |
| CLSCCabana Target Leading Sector Conservative ETF | $19.27 | -0.16% | $24M | — |
| CRUZDefiance Hotel, Airline, and Cruise ETF | $21.88 | +0.03% | $22M | — |
| CSAVictoryShares US Small Cap Volatility Wtd ETF |
No one on the platform currently holds IPDP.
No tracked institution reports a position in IPDP as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-06-25 | $0.2000 | 2025-06-26 |
| 2025-03-26 | $0.1967 | 2025-03-27 |
| 2024-12-24 | $0.1951 | 2024-12-26 |
| 2024-09-26 | $0.1963 | 2024-09-27 |
| 2024-06-27 | $0.1852 | 2024-06-28 |
| 2024-03-27 | $0.1874 | 2024-04-01 |
| 2023-12-22 | $0.1690 | 2023-12-27 |
| 2023-09-26 | $0.1500 | 2023-09-28 |
No one on the platform has traded IPDP yet.
| $66.16 |
| +1.13% |
| $24M |
| — |
| FTDSFirst Trust Dividend Strength ETF | $61.36 | -0.35% | $33M | — |
| OPPXCorbett Road Tactical Opportunity ETFNew | $22.33 | +0.00% | $22M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Dividend Performers ETF. Is that bullish or bearish? $IPDP #RsiOversold #BATS
View on StockTwits ↗$IPDP Indaptus therapeutics- Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.” In this presentation, Dr. Newman will discuss: The science behind Indaptus’ Decoy platform, a multi-immune receptor agonist designed to trigger broad innate and adaptive immune activation against tumors. How the Company’s “Pulse-Prime” approach supports safe and effective anti-tumor activity in pre-clinical models, including the role of Natural Killer (NK) cells. Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors. $MRK #checkpointinhibitors $ONC clinical supply agreement partner https://finance.yahoo.com/news/indaptus-therapeutics-chief-scientific-officer-130000004.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.